Endologix (NASDAQ:ELGX) was downgraded by equities research analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Sunday.
Other analysts have also recently issued reports about the company. Canaccord Genuity restated a “hold” rating and set a $5.00 price target on shares of Endologix in a report on Wednesday, November 8th. Piper Jaffray Companies restated an “overweight” rating on shares of Endologix in a report on Tuesday, December 12th. Royal Bank of Canada restated a “hold” rating and set a $5.00 price target on shares of Endologix in a report on Tuesday, October 3rd. BidaskClub cut Endologix from a “buy” rating to a “hold” rating in a report on Friday, December 15th. Finally, Stifel Nicolaus reduced their price target on Endologix from $6.00 to $5.50 and set a “hold” rating on the stock in a report on Wednesday, November 8th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has issued a buy rating to the stock. Endologix currently has a consensus rating of “Hold” and a consensus price target of $5.41.
Endologix (ELGX) opened at $5.35 on Friday. The company has a market capitalization of $446.48, a PE ratio of -5.75 and a beta of 0.72. The company has a debt-to-equity ratio of 2.61, a quick ratio of 2.11 and a current ratio of 2.90. Endologix has a 52 week low of $4.08 and a 52 week high of $7.66.
ILLEGAL ACTIVITY WARNING: This article was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another website, it was illegally stolen and reposted in violation of international trademark & copyright laws. The legal version of this article can be accessed at https://www.chaffeybreeze.com/2018/01/01/endologix-elgx-cut-to-strong-sell-at-valuengine.html.
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Receive News & Ratings for Endologix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix and related companies with MarketBeat.com's FREE daily email newsletter.